BridgeBio Pharma Inc
BBIO
ISIN null / Valor 48204826
BridgeBio Pharma Inc
UMushroom community rating:
About company
BridgeBio Pharma Inc. is a publicly traded biopharmaceutical company (Nasdaq: BBIO) based in Palo Alto, California, that develops targeted therapies for genetically defined diseases and select cancers. It builds a diversified pipeline of discovery- and development-stage programs—often organized into focused operating subsidiaries—using genetic and biomarker data to guide patient selection and clinical strategy, and advancing candidates through clinical trials toward regulatory approval and commercialization through a mix of in-house development, partnerships and licensing. The company’s business model emphasizes translating genetic insights into precision medicines for rare and oncology indications while managing program-specific risk and capital allocation across its portfolio.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
13029 M
Market cap (USD)
2,925,197
Daily traded volume (Shares)
27.93 / 27.25
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
